Case file
Marion Biotech (Noida, Uttar Pradesh)
Last checked 19 September 2026. Some details are still being verified.
Marion Biotech, a Noida manufacturer, made Ambronol syrup and DOK-1 Max syrup and tablets, which the Uzbek health ministry linked to the deaths of children from acute kidney injury in late 2022. Laboratory testing found diethylene glycol and ethylene glycol, and the WHO issued Medical Product Alert N°1/2023 on 11 January 2023. The Uttar Pradesh licensing authority cancelled Marion Biotech's manufacturing licence in March 2023 after CDSCO testing found a large share of samples adulterated, and company officials were arrested. A 2024 report that the firm was to resume operations means its current licence status must be verified.
Status as of 19 September 2026
WHO Medical Product Alert N°1/2023: Substandard (contaminated) liquid dosage medicines
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Affected products and batches
| Product | Batch | Note |
|---|---|---|
| Ambronol Syrup | , being verified | DEG/EG contamination |
| DOK-1 Max Syrup | , being verified | DEG/EG contamination |
Current status
Licence cancelled in March 2023; a 2024 report indicated the firm sought to resume operations. Current status is flagged for verification as of 19 Sep 2026.
What to do if you have this product
Step 1
Do not use Ambronol or DOK-1 Max syrups of any batch.
Step 2
Any Marion Biotech product should be checked with a pharmacist against current licensing status.
Official sources and primary records
- WHO Medical Product Alert N°1/2023: Substandard (contaminated) liquid dosage medicinesWHOWorld Health Organization · 11 January 2023
- Medical Dialogues: Manufacturing licence of Marion Biotech cancelled by UP authority over cough syrup adulterationNewsMedical Dialogues